These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 827448)

  • 1. Urinary excretion of 5-hydroxyindoles as an indicator of in vivo growth of P815X2 mastocytoma.
    Raikow RB; Schenken LL; Lesher S
    Eur J Cancer (1965); 1976 Dec; 12(12):1011-5. PubMed ID: 827448
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. V. Spleen immunoreactivity and cell mediated cytotoxicity.
    Laatikainen A; Syrjänen K; Mäntyjärvi R; Tosi P
    Arch Geschwulstforsch; 1987; 57(4):265-74. PubMed ID: 3118852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. I. Morphometric assessment of lymph node immunoreactivity and analysis of circulating antibodies.
    Tosi P; Syrjänen K; Cintorino M; Mäntyjärvi R; Luzi P; Miracco C; Laatikainen A; Leoncini L; Santopietro R
    Exp Pathol; 1986; 30(2):65-74. PubMed ID: 3096773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of solid P815x2 murine mastocytoma with adriamycin (NSC-1231127): toxity limitations.
    Schenken LL; Poulakos L; Hagemann RF; Burholt D; Lesher S
    J Natl Cancer Inst; 1976 Mar; 56(3):683-5. PubMed ID: 815561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A procedure for the quantitative separation of viable and non-viable P815X2 mastocytoma cells.
    Wilbur SM; Dettman GL
    J Immunol Methods; 1976; 11(3-4):213-23. PubMed ID: 819586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of local tumor growth with combined fractionated radiotherapeutic and chemotherapeutic regimens.
    Poulakos L; Schenken LL; Hagemann RF; Burholt DR; Lesher S
    J Natl Cancer Inst; 1975 May; 54(5):1103-5. PubMed ID: 805253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. III. Morphometric assessment of the dynamic changes in post-capillary venules as regulatory elements of lymphocyte recirculation in tumor-draining lymph nodes.
    Tosi P; Syrjänen K; Cintorino M; Mäntyjärvi R; Luzi P; Miracco C; Laatikainen A; Leoncini L; Santopietro R
    Arch Geschwulstforsch; 1987; 57(1):7-15. PubMed ID: 3105513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urinary 5-hydroxyindoleacetic acid as an indicator of the in vivo growth of mastocytoma cells].
    Nakamura W; Nishimoto Y
    C R Seances Soc Biol Fil; 1972; 166(8):1182-8. PubMed ID: 4633843
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. VI. Histamine-induced suppression of in vitro generation of tumour-specific cytotoxic T cells.
    Laatikainen A
    Scand J Immunol; 1989 Oct; 30(4):449-55. PubMed ID: 2510290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses of an experimental solid tumour to irradiation: A comparison of modes of fractionation.
    Schenken LL; Poulakos L; Hagemann RF
    Br J Cancer; 1975 Feb; 31(2):228-36. PubMed ID: 809050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spleen white pulp morphology as an indicator of the immunological state in DBA/2 mice bearing mastocytoma.
    Syrjänen KJ
    Exp Pathol (Jena); 1980; 18(4):223-31. PubMed ID: 6772464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. IV. Lymph node immunoreactivity and cell-mediated cytotoxicity.
    Laatikainen A; Syrjänen K; Mäntyjärvi R; Tosi P
    Neoplasma; 1987; 34(4):431-9. PubMed ID: 3116439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection and isolation of a new variant of DBA/2 mastocytoma P 815 X 2.
    Bandlow G; Härtl R
    J Cancer Res Clin Oncol; 1989; 115(6):550-3. PubMed ID: 2514187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined-modality oncotherapy with cyclophosphamide (NSC-26271) and radiotherapy: control of murine mastocytoma.
    Schenken LL; Hagemann RF; Burholt DR; Lesher S
    J Natl Cancer Inst; 1976 Oct; 57(4):943-9. PubMed ID: 826650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of 5-hydroxytryptophan on radiosensitivity of cells in vitro].
    Toyoshi K; Nakamura W; Eto H
    Yakugaku Zasshi; 1969 Oct; 89(10):1469-73. PubMed ID: 4982097
    [No Abstract]   [Full Text] [Related]  

  • 16. Antigenic changes of DBA/2J mastocytoma cells when grown in the BALB/c mouse.
    Wolf JE; Faanes RB; Choi YS
    J Natl Cancer Inst; 1977 May; 58(5):1407-12. PubMed ID: 67213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of tumor growth in the ears of mice.
    Maia LC; Guerra RN; Rossi MI
    J Immunol Methods; 1982 Nov; 55(1):135-9. PubMed ID: 6818280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and partial characterization of a tumor-associated antigen of the P815 mastocytoma of DBA/2 mice.
    Al-Rammahy AK; Levy JG; Jackson AL
    J Immunol; 1980 Jan; 124(1):143-50. PubMed ID: 6765966
    [No Abstract]   [Full Text] [Related]  

  • 19. Preparation and properties of antisera directed against antigens of the P-815 mastocytoma cell not shared by its syngeneic host, the DBA/2 mouse.
    Bertschmann M; Clemetson KJ; Lüscher EF
    Eur J Cancer (1965); 1976 Apr; 12(4):255-62. PubMed ID: 60238
    [No Abstract]   [Full Text] [Related]  

  • 20. [Humoral mechanisms of the membrano-toxic effects of mastocytoma P815 and leukemia EL4 cells].
    Medvedev AE; Fuks BB
    Biull Eksp Biol Med; 1989 Aug; 108(8):194-6. PubMed ID: 2508789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.